Core Insights - Exicure, Inc. (NASDAQ:XCUR) stock experienced a significant increase of 63.23%, reaching $8.70, following the announcement of positive results from its Phase 2 trial of burixafor in multiple myeloma patients [6] Group 1: Trial Results - Approximately 90% of study participants achieved the primary endpoint of collecting ≥2 × 10⁶ CD34+ cells/kg within two leukapheresis sessions [2][3] - Among the 19 participants, 17 (89.5%) met the primary endpoint, with two requiring an additional session to achieve the target [3] - The median time to neutrophil engraftment was 13 days, and the median time to platelet engraftment was 17.5 days for those who proceeded to transplant [4] Group 2: Mechanism and Efficacy - Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors, facilitating rapid mobilization of hematopoietic progenitor cells from the bone marrow [2] - The combination of burixafor with propranolol enhanced mobilization by inhibiting the β2-adrenergic receptor [3] - Peak peripheral levels of CD34+ cells were observed within one hour of burixafor administration, allowing for same-day administration and apheresis [4] Group 3: Safety Profile - The burixafor combination was well tolerated, with no related adverse events exceeding Grade 2 [6] - Among participants with prior exposure to daratumumab, 87.5% achieved the primary endpoint, indicating the treatment's effectiveness even in previously treated patients [5]

Financial Performance & Growth - Ligand预计2025年版税收入超过1.5亿美元，同比增长约40%[5] - Ligand预计2025年核心收入为2.25亿美元至2.35亿美元[39] - Ligand预计2025年调整后核心每股收益为7.40美元至7.65美元，同比增长约31%[40] - Ligand预计2025年运营现金流约为1.75亿美元[41] - Ligand预计2026年版税收入为2亿美元至2.25亿美元，同比增长约40%[45] - Ligand预计2026年总收入为2.45亿美元至2.85亿美元，同比增长约15%[45] - Ligand预计2026年调整后核心每股收益为8.00美元至9.00美元，同比增长约13%[45] - Ligand预计2025-2030年版税收入复合年增长率达到或超过23%[7] Investment & Portfolio - Ligand拥有约10亿美元的可部署资本，包括约6.65亿美元的现金和投资[5] - Ligand在过去两年中已承诺超过4亿美元用于11项投资[82] - Ligand审查了超过170项投资，签署了69项保密协议，完成了6项投资[5, 81]

TAMPA, Fla., Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 9,462,423 shares of its common stock, Series A warrants to purchase up to an aggregate of 9,462,423 shares of its common stock and Series B warrants to purchase up to an aggregate of 9,462,4 ...

Core Viewpoint - Wave Life Sciences' obesity candidate drug WVE-007 shows promising mid-stage results from its Phase I INLIGHT trial, leading to a significant stock price increase [1] Group 1: Trial Results - The Phase I INLIGHT trial involved 32 subjects who received a single 240mg subcutaneous injection of WVE-007 [1] - After 12 weeks, visceral fat decreased by 9.4% (p=0.02), total body fat reduced by 4.5%, and lean body mass increased by 3.2% (approximately 4 pounds) [1] - Overall weight decreased by only 0.9% due to muscle gain offsetting fat loss [1] Group 2: Drug Efficacy - Serum Activin E levels reached a maximum suppression of 78% at 43 days post-injection, with efficacy maintained for over 85 days [1] - The results support the potential for annual or biannual dosing of WVE-007 [1]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, highlighting its expertise in complex securities cases [4].

Game Changing Signals from Global Regulatory Agencies Accompany IVRO Sales and Profit GainsDecember 09, 2025 9:00 AM EST | Source: InVitro InternationalPlacentia, California--(Newsfile Corp. - December 9, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25 sales of $878,937, up 8.3% over FY '24. Net income of $121,980 advanced 14.3% for the same period. CEO and Chairman, W. Richard Ulmer, offered his view of IVRO's progress: "In this past year, Regulatory Agencies around the wor ...

Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its successful participation in the prestigious 9th Healthcare Expo Taiwan, which was held from December 4-7, 2025, at TaipeiNEX 1. The Company exhibited at Booth No. 4F, M1004, where it presented its latest advances in three core portfolios: early cancer detection power ...

Core Points - Novo Nordisk has completed the acquisition of Akero Therapeutics, announced on October 9, 2025, for $54 per share in cash, totaling an aggregated value of $4.7 billion, along with a Contingent Value Right (CVR) that could provide an additional $6 per share upon regulatory approval of Akero's lead candidate EFX [1][2]. Company Overview - Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, efruxifermin (EFX), is currently undergoing three Phase 3 clinical studies [5]. - Novo Nordisk is a global healthcare leader founded in 1923, with a mission to combat chronic diseases, particularly diabetes. The company operates in 80 countries and markets its products in around 170 countries [6].

Core Insights - Akari Therapeutics has announced promising preclinical data for its antibody-drug conjugate (ADC) AKTX-101, which targets Trop2 and shows potential in treating K-Ras G12V mutated pancreatic cancer, a highly lethal form of cancer with low survival rates [1][6] Industry Overview - Pancreatic cancer is one of the deadliest cancers, with approximately 60,000 new diagnoses and around 50,000 deaths annually in the U.S. The most common type, pancreatic ductal adenocarcinoma (PDAC), has limited treatment options, especially for K-Ras G12V mutation-driven tumors [2][3] Current Treatment Landscape - The standard treatments for K-Ras G12V-driven PDAC, such as FOLFIRINOX and gemcitabine plus nab-paclitaxel, yield poor outcomes with overall survival rates of 1.5 years and 1.3 years, respectively. There is a significant unmet need for targeted therapies in this area [3][4] AKTX-101 Mechanism and Efficacy - AKTX-101 is designed to deliver a novel RNA spliceosome modulating payload, PH1, to cancer cells expressing Trop2. This mechanism disrupts RNA splicing, which is crucial for cancer cell survival and proliferation. The ADC has shown significant cytotoxic potency in preclinical models, outperforming other investigational therapies [4][5] Future Development Plans - The company plans to present the preclinical data at a scientific conference and is advancing AKTX-101 towards a first-in-human trial expected to start in late 2026, with preliminary safety and efficacy data anticipated in 2027 [7]

Insilico Medicine aims to list in Hong Kong as soon as this month, sources say, rounding out a more than four-year effort to go public https://t.co/NJC3XkjMxq ...